BioMelbourne Network Progressing BioIndustry

20th May - '2016 Connecting Women Lunch'
SAVE THE DATE for our 2016 Connecting Women Lunch More

BioMelbourne Network

The BioMelbourne Network is a membership based, industry forum representing business leaders in biotechnology, medical technology and innovation industries in Victoria. The power of our network resides with our members, who are some of the largest life sciences companies in Australia. Our mission is to support, connect and enable growth of our sector, through networking and professional development events that provide access to industry intelligence and promote peer-to-peer knowledge exchange.

Invion Receives Notice of Allowance for Patent Rights for the Use of Oral Nadolol in Smoking Cessation

10 March 2016.• OPERATIONAL UPDATE Australian drug development company Invion Limited (ASX:IVX) is pleased to advise that it has received notification of allowance on the patent right for the use of beta-adrenergic inverse agonists for smoking cessation, from the State Intellectual Property Office of the People’s Republic of China. The use of beta-adrenergic inverse agonists for smoking cessa... read more…

Gordagen successful in securing winding-up order against Felda Wellness Corporation

9 March 2016.  ·      Felda Wellness Corporation, a wholly owned subsidiary of FELDA Group, owes debts totalling $652,083.60 to Gordagen Pharmaceuticals Pty. Ltd. and its wholly owned subsidiary Gordagen Pharmaceuticals Manufacturing Pty. Ltd.·      Gordagen and its subsidiary issued statutory demands followed by a winding-up petition in the High Court of Malaysia due to Felda Wellness Corpor... read more…

IDT Australia Expands Revenues from Oncology Drug, Thiotepa

9 March 2016.  • Prices and volumes to rise by more than 50 per cent• IDT extends supply contract, increases flexibility and contracted minimum volumes• AUD12.2-13.4 million in revenues to 2020 9 March 2016, Melbourne: IDT Australia Limited (IDT.AX) has secured an additional four years of contracted earnings for its oncology drug active pharmaceutical ingredient (API) Thiotepa. IDT is one of a... read more…

Nexvet Announces Successful Completion of NV-01 Pilot Field Study

9 March 2016.  Nexvet Announces Successful Completion of NV-01 Pilot Field Study in Dogs With OsteoarthritisEffectiveness Submission to the FDA-CVM on Track for 2Q 2016 DUBLIN, Ireland, March 08, 2016 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, today announced the successful completion of its pilot field study for ranevetmab* (NV-01), the Company's ant... read more…

R&D Tax Incentive: If it ain’t broke, don’t fix it.

4 March 2016.  Amongst the shining announcements in the National Innovation and Science Agenda there's been one thing that's been keeping me awake at night - another review of the R&D Tax Incentive. This highly successful policy programme has helped many Australian biotechnology and medical technology businesses to undertake additional R&D activities and to successfully create innovative healt... read more…

Gordagen to Trial New Drug Delivery Technology from Monash University

24 February 2016.  Gordagen Pharmaceuticals, an Australian nutraceutical and pharmaceutical company, is pleased to announce a collaborative research agreement with Monash University to assess a new drug delivery technology. The research project will assess the feasibility of using a novel, patent-pending lymph directing drug delivery technology.  The technology was developed by researchers at t... read more…

Sue MacLeman Announced as CEO for MPTConnect

22 February 2016.  MTPConnect is pleased to announce that it has appointed Ms Sue MacLeman as Chief Executive Officer.Ms MacLeman will commence her role April in 2016 and will bring energy, expertise and insight to this position.  The industry-led Medical Technologies and Pharmaceuticals Industry Innovation Growth Centre (MTPConnect) has been established under the Australian Government’s Indust... read more…

2016 Premier's Award for Health and Medical Research

19 February 2016.   Today The Premier of Victoria, The Hon. Daniel Andrews MP, and the Minister for Health and Human Services, The Hon. Jill Hennessy MP, called for applications for the 2016 Premier's Award for Health and Medical Research. Please help ensure that any young, up and coming postgraduate health or medical research scholars you know apply for this year's Premier's Award for Health... read more…

New member, directions for Higher Education Standards Panel

10 February 2016.  A leading science and technology advocate will join the Higher Education Standards Panel, strengthening its capacity to advise on issues relating to science, technology, engineering and mathematics (STEM) subjects. Minister for Education and Training Senator Simon Birmingham has reappointed the Chair and members of the Higher Education Standards Panel for a further two year ... read more…

'Bionic spinal cord' trial for humans

9 February 2016.  Trials of the remarkable technology will begin in 2017.  The research has the potential to have a huge impact on paraplegic people.Their limbs won't be reactivated, but the person's direct thought may be able to control equipment that can move the limbs. The device is a minimally invasive brain machine interface - a bionic implant that translates thought into action. It cons... read more…

Davies Collison Cave Welcomes New Partner

9 February 2016.  Davies Collison Cave has expanded its intellectual property practice with the appointment of Dr Gordon Hughes as a new partner. Dr Hughes is a renowned expert in the area of information technology law, data protection, intellectual property commercialisation, and e-commerce and data privacy.  A former partner at Ashurst Australia, Dr Hughes has been a leading figure amongst ... read more…

Nominations for the 2016 BioMelbourne Network 'Women in Leadership'  awards are now open

8 February 2016.  The BioMelbourne Network is very pleased to announce that nominations for the 2016 “Women in Leadership” awards are open! Launched in 2015, these awards celebrate, honour and profile outstanding women in the biotechnology, medical technology and health innovation sector. The ideal candidates will exhibit strong leadership in their fields of expertise, having made outstanding c... read more…

Viralytics Completes $4 Million Share Purchase Plan; Raises Total of $32.4 Million

25 January 2016.  Viralytics Limited (ASX: VLA, OTC: VRACY) today announced the result of the company’s share purchase plan (SPP), which closed on 21 January 2016.Following applications well in excess of $10 million and a scale back the SPP raised a total of $4 million with approximately 6.5 million shares, at $0.615 per share, to be issued to retail investors. This is in addition to the succes... read more…

Phosphagenics Reports Positive Results for Weaner Pig Feed Efficiency Trial

20 January 2016.  Australian drug delivery company, Phosphagenics Limited (ASX: POH; OTCQX: PPGNY), is pleased to report positive results in its initial Animal Health and Nutrition trial. This trial, in more than 1500 weaner (young) pigs, is the first in a series of planned randomized, controlled studies designed to assess if TPM® can enhance the efficiency in which livestock converts feed into... read more…

Gordagen Enters Collaboration Agreement with Japan’s Matsumoto

6 January 2016.  Gordagen Pharmaceuticals, an Australian company developing evidence-based nutraceuticals and pharmaceuticals, today announced it has entered into a Collaborative Product Development Agreement with long-standing Japanese company Matsumoto Trading Co, Ltd. The Agreement covers the development of a new functional food product for the Japanese market, which will incorporate Gordage... read more…

Viralytics Completes $28 million Placement – SPP to Follow

14 December 2015.  Viralytics Limited (Viralytics) announces that it has completed a placement of 46,118,270 shares to international and domestic sophisticated or professional investors at an issue price of $0.615 per share to raise $28,362,736. The placement was significantly oversubscribed with strong demand from international specialist healthcare investment funds, including two New York bas... read more…

Circadian Technologies Changes Name to Opthea

11 December 2015.  Circadian Technologies Limited has changed its name to Opthea Limited (ASX:OPT) effective 9 December 2015.  The name change follows the special resolution passed by shareholders at the Annual General Meeting on 30 November 2015.The Company’s ASX code will change from CIR to OPT.  Trading under the new ASX:OPT code is expected to be effective from 14 December 2015.The name cha... read more…

What do BioMelbourne Network members think about the National Innovation and Science Agenda?

9 December 2015.  Everyone is talking about innovation. The importance of science and technology is being spoken about at the highest levels of government, in the press, on TV and radio, and hopefully in the homes and workplaces of Australians. The Prime Minister's announcement of the National Innovation and Science Agenda feels like an inflection point for Australia. A whole lot of pieces and ... read more…

Phosphagenics’ Animal Health & Nutrition Business Initiates Grower/Finisher Pig Study

3 December 2015.  Australian biotechnology company, Phosphagenics Limited (ASX: POH; OTCQX: PPGNY), is pleased to announce the initiation of the second swine study in its Animal Health and Nutrition “feed efficiency” program.  This study follows-on from the recent successfully completed weaner (young) pig study which is expected to report results later this month. This new study targets older p... read more…

BioMelbourne Network Annual Membership Survey Results

1 December 2015.  We are delighted with the participation from members in our BioMelbourne Network Annual Member Survey, which provided us with some really valuable feedback into the activities and outcomes of the Network in 2015. Thanks our survey sponsors Watermark, who provided a lucky draw prize to delighted winners Gary Haywood from Design and Industry and Alicia Chenoweth from the Burnet ... read more…